0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      2237. Outcomes of Metronidazole Dosed Every 12 Hours Versus Every 8 Hours

      abstract
      , PharmD, BCPS AQ-ID, BCIDP, , PharmD, , PharmD
      Open Forum Infectious Diseases
      Oxford University Press

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Metronidazole (MTZ) is a mainstay treatment for anaerobic infections. Due to its pharmacokinetic and phamacodynamic properties, it can be dosed at 8 -, 12-, or 24-hour intervals. MTZ’s adverse effects depend on the cumulative dose, permitting less frequent administration. Less frequent dosing intervals may save nursing and pharmacy resources and improve patient compliance. Further, drug shortages of IV MTZ have prompted efforts to reduce utilization to preserve the availability of therapy. The objective of this study was to compare clinical outcomes of patients who received MTZ every 8 hours to every 12 hours.

          Methods

          This multicenter, retrospective study was conducted at Scripps Health from 1/1/2022 - 12/31/2022. Hospitalized adult patients who received MTZ, dosed at 500 mg every 8 hours or every 12 hours, for > 5 days for a pulmonary, intra-abdominal, or skin source were included. Patients were excluded if they received anaerobic antibiotics for > 72 hours prior to MTZ or concurrent to MTZ, or were pregnant, transitioned to hospice, or received MTZ for < 75% of the total therapy duration. The primary outcome was clinical cure and all-cause mortality within 30 days. Secondary outcomes were escalation of therapy, 30-day readmission, and duration of therapy.

          Results

          A total of 107 patients were included with similar baseline characteristics per group. The predominant infection source was intra-abdominal (55.1%), followed by skin (29.1%) and pneumonia (12.1%). An anaerobic organism was isolated in 16.8%, and source control was performed in 47.7%. All patients received concurrent antibiotics. Comparing every 8-hour (n = 52) versus every 12-hour (n = 55) MTZ, there was no difference in clinical cure (94.2% vs. 100.0%, p = 0.071) or all-cause mortality (1.9% vs. 0.0%, p = 0.301), respectively. For secondary outcomes, there was no difference in escalation of therapy (3.8% vs. 1.8%, p = 0.525) or 30-day readmission (28.8% vs. 25.5%, p = 0.693) between every 8 hours and every 12 hours. Total duration of antibiotics was similar between groups (14.2 vs 13.0 days, p = 0.541).

          Conclusion

          There was no difference in clinical cure, 30-day all-cause mortality, 30-day readmission, or escalation of therapy among patients receiving every 8 versus every 12-hour MTZ therapy.

          Disclosures

          All Authors: No reported disclosures

          Related collections

          Author and article information

          Contributors
          Journal
          Open Forum Infect Dis
          Open Forum Infect Dis
          ofid
          Open Forum Infectious Diseases
          Oxford University Press (US )
          2328-8957
          December 2023
          27 November 2023
          27 November 2023
          : 10
          : Suppl 2 , IDWeek 2023 Abstracts
          : ofad500.1859
          Affiliations
          Scripps Memorial Hospital La Jolla , La Jolla, California
          Scripps Health , San Diego, California
          Scripps Health , San Diego, California
          Author notes

          Session: 230. Antimicrobial Stewardship: Trends in Antimicrobial Prescribing

          Saturday, October 14, 2023: 12:15 PM

          Article
          ofad500.1859
          10.1093/ofid/ofad500.1859
          10676945
          7bd9f5d0-1a53-46f6-9f60-5413b098769e
          © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

          This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

          History
          Categories
          Abstract
          AcademicSubjects/MED00290

          Comments

          Comment on this article